Biologic Switching and Treatment Effectiveness in JIA

Project Period:
2021-2023

Grant Category:
Small Grant

Disease Area:
Juvenile Idiopathic Arthritis (JIA)

Treatment choices for children with JIA have grown to include several biologics that work on the immune system in different ways. Some children with JIA continue to have active disease even after being on the most commonly used medicines (methotrexate and etanercept). Right now, if a child doesn’t respond to these medicines, we don’t know which medication should be tried next. This study will look at the medications doctors most often tried next for these children and which medications seem to work the best in the “real world”. This will help to answer this important question of what to try next. This study will use information about thousands of children with JIA from 2 large insurance companies in the US. Analyzing this insurance information will let us see how children are actually treated so that we can understand how these treatments are used and how children respond to them.

Investigators

Yukiko Kimura

Hackensack University Medical Center

Related Awarded Grants

Disease Area:
Juvenile Idiopathic Arthritis (JIA)

Genetic Ancestry Powered studies (GAPs) in JIA

Disease Area:
Juvenile Idiopathic Arthritis (JIA)

Pilot of Adalimumab Withdrawal